Please assess the completion status of the following clinical trial:

Trial Title: Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with chronic kidney disease and a glomerular filtration rate within 10-60 ml/min/1.73m2 with no expected need for dialysis during the study~* subjects with a hemoglobin less than 11 g/dL~* subjects who have not received erythropoietic agents within 6 weeks before study entry~* female subjects, with a reproductive potential, must have a negative urine pregnancy test within 7 days of the first dose of study drug.~Exclusion Criteria:~* Subjects with poorly controlled high blood pressure (hypertension) - systolic \> 150 mm Hg or diastolic \> 100 mm Hg~* known hypersensitivity to human albumin and/or mammalian cell-derived products~* subjects receiving dialysis~* subjects with a ferritin level \< 50 ng/mL, Transferrin Saturation \< 20%~* subjects receiving chemotherapy for cancer within 1 month prior to study start or expected during study participation~* Pregnancy or lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).